Global Parkinson's Genetics Program Data Release 8

In September 2024, GP2 announced the eighth data release on the Terra and the Verily® Workbench platforms in collaboration with AMP® PD. This release includes 5,481 additional whole genome sequences and 10,454 clinical exome sequences. Additional genotyping will be provided in the following release.

The whole genome sequencing (WGS) data now consists of a total of 7,734 sequenced participants (6,113 PD cases, 617 Controls, and 1,004 ‘Other’ phenotypes).

When removing the locally-restricted samples, these now consist of 4,713 participants (4,098 PD cases, 390 Controls, and 225 ‘Other’ phenotypes).

Of note, cases recruited via the Monogenic network are coded as ‘Other’

Additionally, included in this WGS release is a partial release of whole genome sequences from two AMP-PD cohorts (BioFind and PPMI) that have been joint-called with GP2 WGS. Released samples can be linked back to the original AMP-PD IDs through an ID crosswalk file included with the release.

This release also includes 10,454 joint-called clinical exome sequencing (CES) participants from the Parkinson’s Foundation.

This release includes a total of 62,087 individuals who have core clinical data available. Among these, 16,800 individuals have deep clinical phenotyping and genetic data available

---

Please see the accompanying blog for further description of this release. To obtain data access, please see https://amp-pd.org/researchers/data-use-agreement. For any publications using data from this release, please reference the DOI number and the following statement: "Data (DOI 10.5281/zenodo.13755496, release 8) used in the preparation of this article were obtained from the Global Parkinson’s Genetics Program (GP2)."